Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

261.80SEK
11:26am BST
Change (% chg)

2.50kr (+0.96%)
Prev Close
259.30kr
Open
257.70kr
Day's High
262.90kr
Day's Low
257.70kr
Volume
137,717
Avg. Vol
877,307
52-wk High
264.30kr
52-wk Low
107.40kr

Select another date:

Fri, Jul 20 2018

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

BRIEF-Sobi appoints Henrik Stenqvist as new CFO

* HENRIK STENQVIST IS JOINING SOBI AS NEW CHIEF FINANCIAL OFFICER

BRIEF-Swedish Orphan Biovitrum says receives positive opinion from CHMP on Anakira

* The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Anakinra for the treatment of Still’s disease.

UPDATE 1-‍Sobi Q4 tops forecast but 2018 outlook below market expectations​

Feb 22 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Thursday a bigger fourth-quarter profit jump than expected but guided for slightly slower profit growth in 2018 than estimated by analysts.

BRIEF-‍Sobi Q4 core profit beats expectations ​

* SAYS ‍SOBI EXPECTS TOTAL REVENUES FOR FULL-YEAR TO BE IN RANGE OF SEK 7,500 - 7,700 M.​

Select another date: